disorders, today announced financial results for the third quarter of 2024 and provided a business update. "We are pleased with the progress we’re making with RAP-219, particularly as we continue the execution of our Phase 2a proof-of-concept trial in focal epilepsy,” said Abraham N. Cees...
Even though the financial markets have started to show improvement, LIDDS continues to assess that it is not in the best interest for the shareholders to try to raise capital thru the market, considering the company’s current valuation. The current focus is to find external party/parties that...
In 2025 alone, we anticipate the first Phase III data for seven new medicines, along with several important new indication opportunities for our existing medicines. We are also investing in and making significant progress with transformative technologies that have the potential to drive our growth ...
Synapse is a global drug intelligence database for pharmaceutical companies, investment institutions and industrial parks. It provides complete and integrated R&D intelligence through artificial intelligence technologies such as natural language processi
Synapse is a global drug intelligence database for pharmaceutical companies, investment institutions and industrial parks. It provides complete and integrated R&D intelligence through artificial intelligence technologies such as natural language processi
Advanced Technologies and Intellectual Property Trends in ADC Research and Development Patsnap Synapse Global Drug R&D Express (Jan 2025) PatSnap Synapse Next-Gen Therapeutics for Fat Loss and Muscle Preservation: Emerging Targets and Strategies
Explore the financial positions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data ...
has not been translated. This review offers a perspective on the use of albumin-based drug delivery systems for a broader range of disease applications, considering the protein properties and a review of the currently approved albumin-based technologies. This review supports ongoing efforts to advance...
Financial Update: The Company had cash, cash equivalents and investments in marketable securities totaling approximately $123 million as of December 31, 2024 (unaudited). The Company expects to significantly reduce its net cash burn in 2025 when compared to 2024. Net cash burn is expected to ...
Advanced Technologies and Intellectual Property Trends in ADC Research and Development Patsnap Synapse Global Drug R&D Express (Jan 2025) PatSnap Synapse Next-Gen Therapeutics for Fat Loss and Muscle Preservation: Emerging Targets and Strategies